Equities Analysts Set Expectations for CVKD Q2 Earnings

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) – Analysts at HC Wainwright lifted their Q2 2026 EPS estimates for shares of Cadrenal Therapeutics in a report issued on Tuesday, July 21st. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings of ($0.95) per share for the quarter, up from their previous forecast of ($1.33). HC Wainwright currently has a “Buy” rating and a $13.00 price target on the stock. The consensus estimate for Cadrenal Therapeutics’ current full-year earnings is ($5.25) per share. HC Wainwright also issued estimates for Cadrenal Therapeutics’ Q3 2026 earnings at ($0.65) EPS, Q4 2026 earnings at ($0.75) EPS, FY2026 earnings at ($3.19) EPS and FY2027 earnings at ($3.09) EPS.

Cadrenal Therapeutics (NASDAQ:CVKD) last released its quarterly earnings results on Thursday, May 7th. The company reported ($1.04) EPS for the quarter, beating the consensus estimate of ($1.51) by $0.47.

A number of other equities research analysts have also recently commented on the company. Wall Street Zen upgraded Cadrenal Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 9th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cadrenal Therapeutics in a report on Friday, July 17th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $13.00.

Cadrenal Therapeutics Stock Performance

Shares of Cadrenal Therapeutics stock opened at $2.03 on Thursday. The firm has a 50-day simple moving average of $3.63 and a two-hundred day simple moving average of $5.45. The company has a market cap of $6.29 million, a P/E ratio of -0.36 and a beta of 1.73. Cadrenal Therapeutics has a fifty-two week low of $1.86 and a fifty-two week high of $14.64.

Institutional Trading of Cadrenal Therapeutics

Several institutional investors have recently modified their holdings of CVKD. DRW Securities LLC acquired a new position in shares of Cadrenal Therapeutics during the 4th quarter worth about $171,000. Geode Capital Management LLC boosted its holdings in Cadrenal Therapeutics by 14.3% in the 4th quarter. Geode Capital Management LLC now owns 14,528 shares of the company’s stock worth $98,000 after buying an additional 1,818 shares during the last quarter. JPMorgan Chase & Co. purchased a new stake in Cadrenal Therapeutics during the 3rd quarter worth approximately $103,000. Finally, Citadel Advisors LLC purchased a new stake in Cadrenal Therapeutics during the 3rd quarter worth approximately $274,000. Institutional investors and hedge funds own 7.92% of the company’s stock.

Insider Buying and Selling

In related news, CEO Quang X. Pham sold 9,029 shares of the business’s stock in a transaction on Friday, June 26th. The shares were sold at an average price of $3.05, for a total value of $27,538.45. Following the completion of the sale, the chief executive officer owned 105,989 shares of the company’s stock, valued at approximately $323,266.45. The trade was a 7.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 97,500 shares of company stock valued at $388,290. 26.09% of the stock is currently owned by insiders.

About Cadrenal Therapeutics

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.